Deals In Depth: May 2013
AbbVie paid $70 million up front in an option-based deal with Alvine, and both Valeant and Actavis completed $8 billion-plus acquisitions, of B&L and Warner Chilcott, respectively. IPOs accounted for $1 billion of the $2.7 billion in biopharma financing; device firms raised $342 million.
You may also be interested in...
The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.
An average price rise of over 1,400% was seen for alendronate 70mg tablets in the UK last month, as average prices for a host of other generics more than doubled.
David Caumartin is well versed in the both the benefits and drawbacks of being a France-based medtech innovator, having spent almost three decades in the local industry. The VP of France Biotech spoke to Medtech Insight about the new opportunities there to be seized, and the pitfalls to avoid.